Aclaris Therapeutics (ACRS) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Oculis (OCS) over the past year, gaining 84.8% versus a loss of 55.4%. Over five years, OCS leads with a -13.4% price change compared with -79.8% for ACRS. Aclaris Therapeutics is the larger company by market cap ($557.9 million vs $533.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | OCS |
|---|---|---|
| Share price | $3.79 | $8.66 |
| Market cap | $557.88M | $533.35M |
| 1-day change | +11.47% | +1.88% |
| YTD return | +12.96% | -57.44% |
| 1-year return | +84.78% | -55.40% |
| 5-year return | -79.77% | -13.44% |
| EPS (TTM) | $-0.58 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $34.48 |
| 52-week low | $1.74 | $8.30 |
| Distance from 52-week high | -42.58% | -74.88% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +168.60% | +321.36% |
| Average volume | 2.48M | 258.13K |
| Shares outstanding | 147.20M | 61.59M |
| Employees | 69 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed OCS by 140.2 percentage points over the past year.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
ACRS vs OCS FAQ
Which is bigger, Aclaris Therapeutics or Oculis?
Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $557.88M compared with $533.35M for Oculis (OCS).
Which stock has performed better over the past year, ACRS or OCS?
ACRS returned +84.78% over the past 12 months, compared with -55.40% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Oculis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.